Entrada Therapeutics, Inc.
TRDA
$8.16
-$0.17-2.04%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 111.85% | -139.57% | 312.25% | 452.05% | 61.25% |
| Total Depreciation and Amortization | 34.78% | 12.35% | 24.66% | 72.64% | 39.92% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 19.06% | 6.67% | 65.34% | -32.64% | -33.69% |
| Change in Net Operating Assets | -1,316.42% | 79.44% | -63.14% | -124.95% | 149.39% |
| Cash from Operations | -687.57% | 0.92% | 213.51% | -112.55% | 85.30% |
| Capital Expenditure | 34.94% | 55.87% | 31.27% | 49.76% | -37.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 169.74% | -3,494.93% | 79.11% | 169.59% | 2.66% |
| Cash from Investing | 180.23% | -2,119.08% | 78.47% | 164.65% | 1.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 103.19% | -- | 22,781.94% | -98.95% | 92.74% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 103.19% | -102.99% | 22,781.94% | -98.95% | 92.74% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 47.34% | -284.78% | 178.98% | -99.54% | 292.79% |